LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Enzon Pharmaceuticals Inc.
Headquarters:
Bridgewater, NJ, United States
Website:
http://www.enzon.com
Year Founded:
1981
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Richard L. Feinstein, CPA
Number Of Employees:
N/A
Enterprise Value:
$7,208,962
PE Ratio:
-4.56
Exchange/Ticker 1:
OTCQB:ENZN
Exchange/Ticker 2:
N/A
Latest Market Cap:
$6,122,700
BioCentury
|
Jun 14, 2017
Distillery Therapeutics
Neurology
Read More
BioCentury
|
Sep 14, 2015
Finance
Gaining leverage
Reading the tea leaves of Icahn's Vivus debt play
Read More
BioCentury
|
May 13, 2015
Company News
Baxter buys Sigma-Tau leukemia portfolio
Read More
BioCentury
|
May 12, 2014
Company News
Enzon infectious news
Read More
BioCentury
|
Dec 16, 2013
Company News
Hologic diagnostic news
Read More
BioCentury
|
Nov 11, 2013
Company News
Enzon, Santaris deal
Read More
BioCentury
|
Sep 5, 2013
Targets & Mechanisms
lncRNA meets the androgen receptor
Read More
BioCentury
|
Apr 29, 2013
Financial News
Enzon financial update
Read More
BioCentury
|
Apr 29, 2013
Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Read More
BioCentury
|
Apr 24, 2013
Financial News
Enzon to distribute royalty cash through dividends
Read More
Items per page:
10
1 - 10 of 236